McKesson Corporation
(MCK)
McKesson's Revenue Miss Is a Mirage
McKesson delivered FY2026 adjusted EPS of $39.11 (+18% year-over-year), beating its own long-range growth targets, and guided FY2027 EPS to $43.80–$44.60 (+12–14%). Q4 revenue of $96.3 billion missed consensus by ~5%, but the miss reflects branded drug price deflation and GLP-...
Read Article ›